| Literature DB >> 26821182 |
Muralidhar Tata1, Michael T Wolfinger2,3, Fabian Amman4,3, Nicole Roschanski1,5, Andreas Dötsch6, Elisabeth Sonnleitner1, Susanne Häussler6,7, Udo Bläsi1.
Abstract
The opportunistic human pathogen Pseudomonas aeruginosa can thrive under microaerophilic to anaerobic conditions in the lungs of cystic fibrosis patients. RNASeq based comparative RNA profiling of the clinical isolate PA14 cultured in synthetic cystic fibrosis medium was performed after planktonic growth (OD600 = 2.0; P), 30 min after shift to anaerobiosis (A-30) and after anaerobic biofilm growth for 96h (B-96) with the aim to reveal differentially regulated functions impacting on sustained anoxic biofilm formation as well as on tolerance towards different antibiotics. Most notably, functions involved in sulfur metabolism were found to be up-regulated in B-96 cells when compared to A-30 cells. Based on the transcriptome studies a set of transposon mutants were screened, which revealed novel functions involved in anoxic biofilm growth.In addition, these studies revealed a decreased and an increased abundance of the oprD and the mexCD-oprJ operon transcripts, respectively, in B-96 cells, which may explain their increased tolerance towards meropenem and to antibiotics that are expelled by the MexCD-OprD efflux pump. The OprI protein has been implicated as a target for cationic antimicrobial peptides, such as SMAP-29. The transcriptome and subsequent Northern-blot analyses showed that the abundance of the oprI transcript encoding the OprI protein is strongly decreased in B-96 cells. However, follow up studies revealed that the susceptibility of a constructed PA14ΔoprI mutant towards SMAP-29 was indistinguishable from the parental wild-type strain, which questions OprI as a target for this antimicrobial peptide in strain PA14.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26821182 PMCID: PMC4731081 DOI: 10.1371/journal.pone.0147811
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
MICs of different antibiotics for B-96 cells versus P cells.
| Class | Antibiotic | Range tested (μg/ml) | MIC (μg/ml)B-96 vs P |
|---|---|---|---|
| Macrolides | Azythromycin | 256–0.25 | >256 vs 2 |
| Quinolones | Ciprofloxacin | 32–0.031 | >32 vs 4 |
| Quinolones | Norfloxacin | 256–0.25 | >256 vs 16 |
| Polymyxins | Colistin | 256–0.25 | 16 vs 2 |
| Aminoglycosides | Gentamycin | 256–0.25 | 64 vs 0.5 |
| Carbapenems | Meropenem | 32–0.031 | >4 vs 0.25 |
| Tetracycline | Tetracycline | 256–0.25 | >256 vs 32 |
Fig 1Meta-analysis of normalized expression of differentially abundant transcripts under the conditions A-30 and B-96 when compared with condition P.
The genes are grouped into the corresponding pathways (http://www.kegg.jp/kegg-bin/show_organism?org=pau). For each group the overall behavior was summarized by the averaged log2 fold change of its significantly modulated members. The column denotes A-30 versus P and B-96 versus P, respectively. The color code shown in the scale at the right denotes log2-fold changes. Red indicates an overall decrease and green indicates an overall increase in the mRNA levels of genes in a particular pathway. The numbers of genes within each group are indicated by the numbers given in parenthesis.
Fig 2Biofilm formation of PA14 and transposon mutants thereof after anaerobic growth in SCFM medium after 96h.
Biofilm formation was quantified by measuring the absorbance at 595 nm after crystal violet staining. The results are averaged from three independent experiments.
Altered abundance of transcripts encoding antibiotic tolerance functions.
Fold change under the condition B-96 when compared with P. Only ≥ ± 5 fold change was considered.
| PA14-ID | Gene | Fold change B-96 vs P | p-value | Substrate(s) | References |
|---|---|---|---|---|---|
| PA14_09500 | -9.78 | 1.02E-53 | Fluoroquinolones | [ | |
| PA14_09520 | -6.03 | 4.33E-22 | ″ | ||
| PA14_09530 | -6.60 | 9.19E-39 | ″ | ||
| PA14_09540 | -4.24 | 8.18E-24 | ″ | ||
| PA14_60810 | 3.60 | 7.34E-03 | Fluoroquinolones, β -lactams, Tetracycline, Chloramphenicol, Macrolides, Trimethoprim, Novobiocin | [ | |
| PA14_60820 | 3.96 | 1.27E-02 | ″ | ||
| PA14_60830 | 6.28 | 5.70E-02 | ″ | ||
| PA14_60850 | 7.81 | 7.22E-02 | ″ | ||
| PA14_60860 | 7.08 | 1.55E-04 | ″ | ||
| PA14_51880 | -5.07 | 2.25E-30 | Carbapenem | [ | |
| -18.26 | 9.42E-54 | hRNase7 and cationic α-helical antimicrobial peptides (AMP) | [ |
Fig 3OprI is not required for susceptibility of PA14 towards the antimicrobial peptide SMAP-29.
A) Determination of the levels of oprI mRNA in P cells (P) and B-96 cells (B-96) by Northern-blot analysis. In-vitro transcribed oprI mRNA (0.5 ng) was used as a control (C). 5S rRNA served as a loading control. B) The strains were grown planktonically to an OD600 of 2.0 in SCFM (P) and for 96 hours under anaerobic conditions (B-96). Then, the cultures were harvested and the β-galactosidase activities were determined. The bars depict β-galactosidase values conferred by the translational OprI-LacZ protein in strain PA14(pTLoprI) under the conditions P and B-96. The error bars represent standard deviations from three independent experiments. C) Susceptibility of PA14 (red) and PA14ΔoprI (green) towards the cationic peptide, SMAP-29, under aerobic conditions. The experiment was performed as outlined in Materials and Methods. D) Determination of the oprI mRNA levels by Northern-blot analysis in strains PA14 and PA14∆oprI at the time of addition of SMAP-29 to the cultures. In vitro transcribed oprI mRNA (1 ng) was used as a control (C). 5S rRNA served as a loading control.